Navigation Links
MDS Inc. Announces Normal Course Issuer Bid
Date:6/30/2008

TORONTO, June 30 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS, NYSE: MDZ), a leading provider of enabling products and services to the global life sciences markets, announced today that the Toronto Stock Exchange (TSX) accepted the Company's Notice of Intention to make a normal course issuer bid for a one-year period.

The Notice provides that during the twelve months commencing July 3, 2008 and ending July 2, 2009, if deemed appropriate by the Chief Executive Officer and Chief Financial Officer of the Company, MDS may purchase up to 4,136,766 MDS Common shares on the Toronto Stock Exchange and the New York Stock Exchange. This represents approximately 5% of the public float. At June 20, 2008, there were 122,028,330 Common shares issued and outstanding and 82,735,313 Common shares in the public float. All shares purchased by MDS under this normal course issuer bid will be promptly cancelled. Daily purchases will be limited to 130,250 Common shares, other than block purchase exceptions.

Under the Company's previous normal course issuer bid, which began on July 3, 2007 and ends on July 2, 2008, MDS has purchased and cancelled 1,235,300 Common shares to date.

Since all purchases of MDS Common shares under the normal course issuer bid would be made on the open market, the Company is not in a position to know the identity of the parties from whom it may purchase Common shares. The Company believes that the purchase of outstanding Common shares at certain times during the normal course issuer bid period may enhance value for shareholders and is an appropriate use of funds.

This document contains forward-looking statements. Some forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "indicates" or similar expressions. The statements are not a guarantee of future performance and are inherently subject to risks and uncertainties. The Company's actual results could differ materially from those currently anticipated due to a number of factors, including, but not limited to, successful integration of structural changes, including restructuring plans, acquisitions, technical or manufacturing or distribution issues, the competitive environment for the Company's products, the degree of market penetration of the Company's products, and other factors set forth in reports and other documents filed by the Company with Canadian and US securities regulatory authorities from time to time.

About MDS

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS Inc. has more than 5,500 highly skilled people in 29 countries. Find out more at http://www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.


'/>"/>
SOURCE MDS Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Medical Machines Online Announces the Overstock and Release of a New ECG Machine
2. BMP Sunstone Announces Official Launch of Ferriprox in PRC
3. Elsevier announces 2007 journal impact factor highlights
4. Response Biomedical Corporation Announces Strategic Partnership with Roche Diagnostics To Commercialize Cardiovascular Tests
5. Microsoft Announces Winners of the 2008 Pharmaceutical and Life Sciences Innovation Awards
6. Hologic, Inc. Announces Grant of Early Termination of Antitrust Waiting Period for Third Wave Technologies, Inc. Tender Offer
7. DST Systems, Inc. Announces Notification of Earnings Release Date
8. A Place for Mom, Nations Largest Assisted Living and Senior Housing Referral Service Announces New Vice President of Finance
9. LCA-Vision Announces CFO Change
10. BD Announces Live Webcast of Third Fiscal Quarter Earnings Conference Call
11. Bally Total Fitness Announces New Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon ... is thrilled to offer the recently FDA-approved Obalon Balloon System to his patients. ... SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu is ...
(Date:3/28/2017)... ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in ... has a lot to offer to the discussion of dealing with excess skin oil. ... there are many home remedies that can help remove the oily shine while keeping the ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... treatment, with or without a referral. Sleep apnea is often left untreated because patients ... morning headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of ...
(Date:3/27/2017)... London UK (PRWEB) , ... March 27, 2017 ... ... agility and ability to gain site attention and engagement over the household brands ... educational webinar will discuss how partnering with the right outsourcing payments ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 28, 2017 The global market ... with the top three companies, namely Shimadzu Corporation, Thermo ... significant 49% of the overall market in 2015, observes ... landscape is intensely competitive and has few players, most ... These factors have restricted the entry of new players ...
(Date:3/28/2017)... TEL AVIV, Israel , March 28, 2017 ... . This new business entity, Emosis Ltd, headquartered in ... and development of novel assays complementing the mother company existing technology ... support commercialization and sales development of Emosis kits. ... This strategic move starts building Emosis ...
(Date:3/28/2017)... 28, 2017  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), ... cancer and other unmet medical needs, announced today ... Cancer Research annual meeting.  The first poster to ... "Evaluation of ENMD-2076 in Combination with Anti-PD1 in ... to be presented on April 4 is entitled ...
Breaking Medicine Technology: